The largest database of trusted experimental protocols

3 protocols using umbralisib

1

Reconstitution and Use of PI3K Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
PI3K inhibitors (duvelisib, idelalisib, umbralisib, eganelisib [all Sellekchem, Munich, Germany]) were reconstituted at a concentration of 20 mM (duvelisib, idelalisib, umbralisib) or 40 mM (eganelisib) in dimethyl sulfoxide (DMSO, Genaxxon Bioscience, Ulm, Germany) and all used at a final concentration of 1 µM in complete medium according to literature.30 (link),31 (link)
+ Open protocol
+ Expand
2

Phospho-specific Flow Cytometry with Barcoding

Check if the same lab product or an alternative is used in the 5 most similar protocols
Phospho-specific flow cytometry with fluorescence cell barcoding were performed as has previously been reported.17 (link) Briefly, cells (either patient samples or cell lines) were plated at 1×106 cells/mL and incubated with either DMSO, umbralisib (Selleck Chemicals, S8194) (20 μM), ruxolitinib (Selleck Chemicals, S1378) (60 nM), or the combination for 30 min. Cells in the stimulated condition were subsequently stimulated with 20 ng/mL GM-CSF (Peprotech, 300–03-20ug) for 15 min and all were then exposed to 50x Ax700 (Invitrogen, A20010) viability stain. Cells were fixed in 1.6% PFA (Fisher Scientific, 50–980-487) in dark at RT for 10 min, washed with PBS, and permeabilized with MeOH (Fisher Scientific, A4121) and stored in −80 °C. Cells were washed twice with PBS before barcoding with serial dilutions of Pacific Orange (1:2.5) (Invitrogen, P30253) and Pacific Blue (1:2.4) (Invitrogen, P10163) dyes and combining in a single tube.18 (link),19 (link) Cells were stained with pSTAT5-PE/Cy7 (Clone 47, BD:560117), pERK-Ax488 (Clone 6B8B69, Biolegend:369508), pAKT-Ax488 (Clone M89–61, Company BD:560404 and Clone D9E, CST:5315S) and pS6-Ax647 (Clone D57.2.2E, Company CST:4851S) in the dark at RT for 30 min. Cells were washed with 1mL PBS/BSA and resuspended in 0.2 mL PBS/BSA and run a 4-laser LSR Fortessa (Becton Dickinson).
+ Open protocol
+ Expand
3

Dose-dependent drug response assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Response to single drugs or drug combinations was assessed after 72 h of exposure to increasing doses of the drug followed by an MTT assay. Copanlisib, duvelisib, umbralisib, everolimus, bimiralisib, vincristine, 5-azacitidine, masitinib, stattic and tocilizumab were purchased from Selleckchem, Lin28-1632 (LIN1632) from R&D Systems (Minneapolis, MN, USA), and human recombinant interleukin 6 (IL-6; CYT-213) from Prospec (Rehovot, Israel). Loncastuximab tesirine was kindly provided by ADC Therapeutics (Epalinges, Switzerland). Details are provided in the Online Supplementary Methods.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!